Immunic (IMUX) Insider Simona Skerjanec Buys 25,370 Shares

Simona Skerjanec acquired 25,370 shares of Immunic, Inc. (IMUX) on June 29, 2026. This transaction was part of a larger cluster of buying by the company's leadership team on that same date. The acquisition was reported in a recent filing, showing the executive's increased stake in the Nasdaq-listed biotechnology firm.

Wide Insider Activity at Immunic

Skerjanec was not the only leader making moves. On June 29, 2026, several other insiders reported similar transactions. Richard Alan Rudick, Barclay Phillips, Tamar Howson, and Joerg Neermann each purchased 25,370 shares. Jon Congleton made an even larger move, acquiring 50,740 shares on that same day. None of these transactions were conducted under a Rule 10b5-1 plan, which is a pre-set schedule insiders sometimes use to trade at specific times regardless of market changes.

Immunic Stock Performance and Outlook

Shares of Immunic traded at $15.41 on Tuesday. This price is closer to the high end of its 52-week range, which spans from $5.06 to $17.43. The stock has been trading at levels higher than its 200-day moving average, a common indicator of a stock's long-term trend. The company currently has a market value of about $147.77 million.

Analysts Set New Price Targets

Financial analysts have been active in reviewing Immunic recently. On September 10, 2026, Wedbush reiterated its Outperform rating with a price target of $45.00. That same day, H.C. Wainwright & Co. kept its Buy rating and a $22.00 price target. Earlier, in August, Wedbush initiated its coverage with the same $45.00 target. With 11 analysts covering the company, the consensus is currently a Strong Buy, and the average price target of $43.09 suggests potential for growth from current trading levels.

Focus on Autoimmune Therapies

Immunic is a biotechnology firm that creates oral therapies for chronic inflammatory and autoimmune diseases. Its most advanced work involves a treatment for multiple sclerosis and ulcerative colitis, which is currently in late-stage clinical trials. The company is also researching ways to restore intestinal health for patients with celiac disease and other gastrointestinal conditions. These insider purchases come as the company continues to move these treatments through the regulatory pipeline.

Looking Ahead for Investors

The next major milestone for the company will be its quarterly earnings report, which is expected on November 12, 2026. Because the firm is still in the development stage for many of its therapies, it does not currently show a profit or a traditional P/E ratio. These insider filings provide a look at what leadership was doing in late June, though these moves are backward-looking and may not reflect their current views on the stock's value today.